Heteroaromatic Carboxamide PKK Inhibitors With Selective Stable Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current plasma kallikrein inhibitors face challenges in achieving high selectivity, metabolic stability, and favorable pharmacokinetic properties while being well-absorbed and non-toxic, particularly for treating inflammatory disorders and edema-associated diseases.
Innovation Solution
Development of novel heteroaromatic carboxamide derivatives that act as potent plasma kallikrein inhibitors, exhibiting enhanced potency, selectivity, metabolic stability, and favorable pharmacokinetic properties, including high solubility and bioavailability, with the potential to form stable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current plasma kallikrein inhibitors are used, then plasma kallikrein inhibition is achieved, but selectivity and metabolic stability are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters including heteroatom types (N, O, S), ring sizes (5-7 membered), substitution patterns, and stereochemistry to optimize both selectivity and metabolic stability. Specific modifications include introducing fluorine atoms at positions 3 and 5 of the pyridine ring, and selecting specific bicyclic ring systems with nitrogen atoms to enhance metabolic stability while maintaining PKK inhibition selectivity.
2Reliability
If plasma kallikrein inhibitors are developed with enhanced potency, then therapeutic effectiveness is improved, but pharmacokinetic properties and solubility may be compromised
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the molecule independently. The core heteroaromatic carboxamide structure provides potent PKK inhibition, while peripheral substituents (bicyclic ring systems, alkyl groups, fluorine atoms) are tailored to improve pharmacokinetic properties. For example, the bicyclic ring system with specific nitrogen positioning enhances oral bioavailability without compromising the inhibitory potency at the active site.
3Object-affected harmful factors
If plasma kallikrein inhibitors are designed for high selectivity, then off-target effects are reduced, but metabolic stability and absorption may be affected
Solution Approach 1:
The patent applies composite materials by combining multiple structural elements with complementary functions: heteroaromatic carboxamide core for selective PKK binding, fluorinated pyridine ring for enhanced metabolic stability, and bicyclic ring systems for improved oral absorption. This composite molecular architecture achieves high selectivity while maintaining metabolic stability and favorable pharmacokinetic properties.
Data Source
AI summary
Disclosed are heteroaromatic carboxamides of formula (I),wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.